Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Cardiology

The Blueprint of the Heart: Genetics and Biology of FIDC

At a Glance

Familial Isolated Dilated Cardiomyopathy (FIDC) is caused by inherited genetic mutations in genes like TTN and LMNA. These mutations weaken the heart muscle, causing it to stretch. Knowing your specific gene helps your cardiologist predict disease progression and customize your care plan.

While most heart problems are caused by external factors like high blood pressure or blocked arteries, Familial Isolated Dilated Cardiomyopathy (FIDC) begins deep within the biology of the heart cells themselves [1]. In FIDC, your DNA contains a “misspelling” (mutation) that affects how the heart is built or how it functions [2]. Think of these mutations as “bad actors” that prevent the heart muscle from staying strong and compact, causing it to stretch out and weaken over time [3][4].

The Blueprint: Five Key Genes

Scientists have identified several specific genes that are frequently responsible for FIDC. Each gene has a different “job” in the heart, and knowing which one is affected helps your doctor predict how the disease might behave.

  • TTN (Titin): The Spring. Titin is the largest protein in the human body and acts like a molecular spring that helps the heart muscle bounce back after each beat [3]. Mutations in TTN are the most common cause of genetic DCM [5]. While it causes the heart to enlarge, many patients with this variant respond very well to standard heart medications [6].
  • LMNA (Lamin A/C): The Envelope. This protein forms a protective “envelope” around the nucleus (the control center) of every heart cell, providing structural stability [7]. Mutations here can make the cells fragile [8]. LMNA is considered a high-risk gene because it often causes electrical rhythm problems (arrhythmias) long before the heart’s pumping strength starts to fail [9][10].
  • FLNC (Filamin C): The Anchor. FLNC helps anchor the internal structures of the heart cell to its outer wall [11]. Like LMNA, mutations in FLNC are known for an “arrhythmogenic” phenotype, meaning they carry a higher risk of dangerous heart rhythms and sudden cardiac events [12][13].
  • RBM20: The Editor. This gene doesn’t build the heart directly; instead, it acts like a film editor, “splicing” together the instructions for other proteins (including Titin) [14]. If the editor is broken, the heart is built with faulty parts, often leading to a more aggressive form of the disease that can appear earlier in life [15][16].
  • MYH7: The Motor. This gene provides instructions for the “heavy lifting” protein that allows heart cells to contract [17]. Mutations in MYH7 can cause the heart muscle to struggle with its basic motor function, sometimes leading to rapid progression toward heart failure [18].

Why Your Doctor Ran So Many Tests

One of the most important steps in your diagnosis is distinguishing FIDC from other common heart conditions that look similar on an ultrasound. This helps contextualize why you likely had to undergo angiograms, MRIs, and extensive blood work [2][4].

Feature FIDC (Genetic) Ischemic Heart Disease (Acquired)
Root Cause Inherited DNA mutation [1] Blocked or “clogged” arteries [4]
Family History Often multiple relatives affected [19] May or may not have a family history
MRI Findings Scarring often in the middle of the wall [20] Scarring typically on the inner lining [21]
Other Triggers Genetic susceptibility [2] High cholesterol, smoking, diabetes

It is important to note that having a genetic mutation doesn’t mean you are immune to common heart disease. A patient with FIDC can also develop clogged arteries from high cholesterol or smoking. This is why controlling your traditional risk factors remains vitally important even with a genetic diagnosis.

Doctors also check for “look-alikes” such as viral myocarditis (inflammation from a virus), alcohol or toxin exposure, and thyroid disorders [22][23]. While these can also cause the heart to dilate, FIDC is unique because the problem is written into the genetic blueprint of the heart itself [2][24].

To see how these changes are captured on your medical tests, refer to Diagnosis & Understanding Your Reports for FIDC.

Common questions in this guide

What are the most common genes that cause FIDC?
Scientists have identified several key genes responsible for Familial Isolated Dilated Cardiomyopathy. The most common is the TTN gene, but others include LMNA, FLNC, RBM20, and MYH7, each affecting the heart's structure and function differently.
Why is the LMNA gene mutation considered high-risk?
Mutations in the LMNA gene can make heart cells fragile and frequently cause dangerous electrical rhythm problems. These arrhythmias can occur long before the heart's pumping strength actually starts to fail, which is why it is considered a high-risk variant.
How does a genetic enlarged heart differ from one caused by clogged arteries?
FIDC is caused by an inherited DNA mutation that changes how the heart muscle is built. In contrast, ischemic heart disease is an acquired condition where blocked or clogged arteries prevent blood flow, often related to lifestyle factors like smoking or high cholesterol.
Can I still get common heart disease if I have FIDC?
Yes, having a genetic heart condition does not make you immune to traditional heart disease. Patients with FIDC can still develop clogged arteries from high cholesterol, diabetes, or smoking, making it vital to manage all risk factors.
Will my specific genetic variant change my treatment plan?
Yes, knowing your specific gene mutation helps doctors predict how the disease will behave. For example, variants like LMNA or FLNC have a higher risk for arrhythmias, which might mean you need earlier discussions about an implantable cardioverter-defibrillator (ICD) or more frequent monitoring.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my genetic test, which specific protein is affected—is it a structural protein, a 'motor' protein, or a 'splicing' regulator?
  2. 2.Does my genetic variant (especially if it's LMNA, FLNC, or RBM20) increase my risk for arrhythmias even if my heart's pumping strength is still okay?
  3. 3.How did you rule out 'clogged pipes' (ischemic disease) or previous viral infections as the primary cause of my heart's enlargement?
  4. 4.Will my specific genetic variant change the way you monitor me—for example, will I need more frequent heart rhythm monitoring or an earlier conversation about an ICD?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    Small RNA-sequencing identified the potential roles of neuron differentiation and MAPK signaling pathway in dilated cardiomyopathy.

    Huang G, Cao M, Huang Z, et al.

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2019; (114()):108826 doi:10.1016/j.biopha.2019.108826.

    PMID: 30948207
  2. 2

    Risk Assessment and Personalized Treatment Options in Inherited Dilated Cardiomyopathies: A Narrative Review.

    Arnautu DA, Cozma D, Lala IR, et al.

    Biomedicines 2024; (12(8)) doi:10.3390/biomedicines12081643.

    PMID: 39200108
  3. 3

    Genomics-First Evaluation of Heart Disease Associated With Titin-Truncating Variants.

    Haggerty CM, Damrauer SM, Levin MG, et al.

    Circulation 2019; (140(1)):42-54 doi:10.1161/CIRCULATIONAHA.119.039573.

    PMID: 31216868
  4. 4

    Pathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine.

    Gigli M, Stolfo D, Merlo M, et al.

    Nature reviews. Cardiology 2025; (22(3)):183-198 doi:10.1038/s41569-024-01074-2.

    PMID: 39394525
  5. 5

    Molecular studies in familial dilated cardiomyopathy - A pilot study.

    Mori V, Sawhney JPS, Verma IC, et al.

    International journal of cardiology. Heart & vasculature 2022; (40()):101023 doi:10.1016/j.ijcha.2022.101023.

    PMID: 35463915
  6. 6

    Association of Titin-Truncating Genetic Variants With Life-threatening Cardiac Arrhythmias in Patients With Dilated Cardiomyopathy and Implanted Defibrillators.

    Corden B, Jarman J, Whiffin N, et al.

    JAMA network open 2019; (2(6)):e196520 doi:10.1001/jamanetworkopen.2019.6520.

    PMID: 31251381
  7. 7

    Genotype-specific pathogenic effects in human dilated cardiomyopathy.

    Bollen IAE, Schuldt M, Harakalova M, et al.

    The Journal of physiology 2017; (595(14)):4677-4693 doi:10.1113/JP274145.

    PMID: 28436080
  8. 8

    An integrative approach to identify novel miRNA-mRNA interaction networks in LMNA-cardiomyopathy.

    Córdoba-Caballero J, Bonet F, Campuzano O, et al.

    Scientific reports 2026; (16(1)):6110.

    PMID: 41580472
  9. 9

    Emerging concepts in arrhythmogenic dilated cardiomyopathy.

    Zegkos T, Panagiotidis T, Parcharidou D, Efthimiadis G

    Heart failure reviews 2021; (26(5)):1219-1229 doi:10.1007/s10741-020-09933-z.

    PMID: 32056050
  10. 10

    Troponin T Assessment Allows for Identification of Mutation Carriers among Young Relatives of Patients with LMNA-Related Dilated Cardiomyopathy.

    Chmielewski P, Kowalik I, Truszkowska G, et al.

    Journal of clinical medicine 2024; (13(11)) doi:10.3390/jcm13113164.

    PMID: 38892874
  11. 11

    Filamin C Truncation Mutations Are Associated With Arrhythmogenic Dilated Cardiomyopathy and Changes in the Cell-Cell Adhesion Structures.

    Begay RL, Graw SL, Sinagra G, et al.

    JACC. Clinical electrophysiology 2018; (4(4)):504-514 doi:10.1016/j.jacep.2017.12.003.

    PMID: 30067491
  12. 12

    Truncating mutations on myofibrillar myopathies causing genes as prevalent molecular explanations on patients with dilated cardiomyopathy.

    Janin A, N'Guyen K, Habib G, et al.

    Clinical genetics 2017; (92(6)):616-623 doi:10.1111/cge.13043.

    PMID: 28436997
  13. 13

    Dilated cardiomyopathy: the role of genetics, highlighted in a family with Filamin C (FLNC) variant.

    Dungu JN, Langley SG, Hardy-Wallace A, et al.

    Heart (British Cardiac Society) 2022; (108(9)):676-682 doi:10.1136/heartjnl-2021-319682.

    PMID: 34417207
  14. 14

    Precise genomic editing of pathogenic mutations in RBM20 rescues dilated cardiomyopathy.

    Nishiyama T, Zhang Y, Cui M, et al.

    Science translational medicine 2022; (14(672)):eade1633 doi:10.1126/scitranslmed.ade1633.

    PMID: 36417486
  15. 15

    RBM20 p.Arg636Cys: A Pathogenic Variant Identified in a Family with Several Cases of Unexpected Sudden Deaths.

    Lorca R, Alén A, Salgado M, et al.

    Journal of clinical medicine 2025; (14(3)) doi:10.3390/jcm14030743.

    PMID: 39941414
  16. 16

    RNA sequencing reveals abnormal LDB3 splicing in sudden cardiac death.

    Yamamoto T, Miura A, Itoh K, et al.

    Forensic science international 2019; (302()):109906 doi:10.1016/j.forsciint.2019.109906.

    PMID: 31419596
  17. 17

    Natural History of MYH7-Related Dilated Cardiomyopathy.

    de Frutos F, Ochoa JP, Navarro-Peñalver M, et al.

    Journal of the American College of Cardiology 2022; (80(15)):1447-1461 doi:10.1016/j.jacc.2022.07.023.

    PMID: 36007715
  18. 18

    Cardiac-Specific Cre Induces Age-Dependent Dilated Cardiomyopathy (DCM) in Mice.

    Rehmani T, Salih M, Tuana BS

    Molecules (Basel, Switzerland) 2019; (24(6)) doi:10.3390/molecules24061189.

    PMID: 30917606
  19. 19

    Non-ischaemic dilated cardiomyopathy: recognising the genetic links.

    Paul C, Peters S, Perrin M, et al.

    Internal medicine journal 2023; (53(2)):178-185 doi:10.1111/imj.15921.

    PMID: 36043846
  20. 20

    Association Between Midwall Late Gadolinium Enhancement and Sudden Cardiac Death in Patients With Dilated Cardiomyopathy and Mild and Moderate Left Ventricular Systolic Dysfunction.

    Halliday BP, Gulati A, Ali A, et al.

    Circulation 2017; (135(22)):2106-2115 doi:10.1161/CIRCULATIONAHA.116.026910.

    PMID: 28351901
  21. 21

    Cardiac sarcoidosis with severe involvement of the right ventricle: a case report.

    Siqueira WC, da Cruz SG, Asimaki A, et al.

    Autopsy & case reports 2015; (5(4)):53-63 doi:10.4322/acr.2015.030.

    PMID: 26894046
  22. 22

    Nonischemic cardiomyopathy with reduced ejection fraction secondary to hyperthyroidism.

    Martin MM, Collins MR

    JAAPA : official journal of the American Academy of Physician Assistants 2021; (34(6)):27-30 doi:10.1097/01.JAA.0000735812.69357.c5.

    PMID: 34031311
  23. 23

    Combination therapy of liothyronine and levothyroxine for hypothyroidism-induced dilated cardiomyopathy.

    Choi Y, Jung SY, Park JM, et al.

    Annals of pediatric endocrinology & metabolism 2023; (28(2)):144-148 doi:10.6065/apem.2142218.109.

    PMID: 35718890
  24. 24

    Truncating Titin and Lamin A/C Variants in Anthracycline-Induced Cardiomyopathy.

    Advani PP, McPherson AD, Reddy JS, et al.

    JACC. Advances 2026; (5(2)):102431 doi:10.1016/j.jacadv.2025.102431.

    PMID: 41379058

This page explains the genetics and biology of Familial Isolated Dilated Cardiomyopathy (FIDC) for educational purposes only. Always consult your cardiologist or genetic counselor for advice specific to your diagnosis and treatment.

Get notified when new evidence is published on Familial isolated dilated cardiomyopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.